Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: A Finnish perspective

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 59, Issue 3, 2005, Pages 397-405

  Närhi, Marko ^a   Nordström, Katrina ^a  

^a AALTO UNIVERSITY   (Finland)

Author keywords

Biopharmaceuticals; Biotech engineering; FDA EMEA regulations; GMP; Manufacturing; Scale up

Indexed keywords

ARTICLE; DRUG INDUSTRY; FINLAND; FOOD AND DRUG ADMINISTRATION; MEDICAL LITERATURE; MOLECULAR DYNAMICS;

EID: 14844317383     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.11.006     Document Type: Article

References (31)

1. C. Boswell Custom manufacturers see growth in biopharmaceuticals Chem. Mark. Rep. 261 10 2002 FR9 FR10
2. G. Walsh Pharmaceutical biotechnology products approved within the European Union Eur. J. Pharm. Biopharm. 55 2003 3 10
3. PhRMA, New Medicines in Development for Biotechnology, 2002, http://www.phrma.org
4. C. Christy, and S. Vermant The state-of-the-art of filtration in recovery processes for biopharmaceutical production Desalination 147 2002 1 4
5. T. Mitchell Biotechnology facility design: a rationale for compliance Regul. Aff. Focus 7 6 2002 18 21
6. V. Anghel, and D.G. Chetwynd Creating a low-cost, ultra-clean environment Prec. Eng. 26 2002 122 127
7. C. Boswell A time of ferment for biopharmaceutical contract manufacturing Chem. Mark. Rep. 259 11 2001 FR11 FR13
8. C.R. Lowe, A.R. Lowe, and G. Gupta New developments in affinity chromatography with potential application in the production of biopharmaceuticals J. Biochem. Biophys. Methods 49 2001 561 574
9. F. Hesse, and R. Wagner Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures Trends Biotechnol. 18 2000 173 180
10. European Commission, Commission Directive 2003/94/EC, O.J. 46(L 262) (2003) 0022-0026.
11. H. Schellekens, and J.-C. Ryff 'Biogenerics': the off-patent biotech products Trends Pharmacol. Sci. 23 2002 119 121
12. J. Sims Assessment of biotechnology products for therapeutic use Toxicol. Lett. 120 2001 59 66
13. Committee for Proprietary Medicinal Products, Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues, EMEA/CPMP/BWP/3207/00/Rev 1 December 2003, http://www.emea.eu.int/pdfs/human/bwp/320700en.pdf
14. O. Doblhoff-Dier, and R. Bliem Quality control and assurance from the development to the production of biopharmaceuticals Trends Biotechnol. 17 1999 266 270
15. R. Lähteenmäki Finnish biotechnology - build on solid foundations Nat. Biotechnol. 20 2002 437 440
16. A.P.J. Middelberg Preparative protein refolding Trends Biotechnol. 20 2000 437 443
17. F. Hesse, and R. Wagner Development and improvements in the manufacturing of human therapeutics with mammalian cell cultures Trends Biotechnol. 18 2000 173 180
18. European Commission, Commission Directive 2003/63/EC. O.J. 46(L159) (2003) 0046-0094.
19. Department of Health and Human Services, Pharmaceutical cGMPs for the 21st Century - a Risk-Based Approach Final Report, September 2004, http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm
20. Department of Health and Human Services, Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, September 2004, http://www.fda.gov/cder/guidance/6419fnl.htm
21. M. Thiry, and D. Cingolani Optimizing scale-up fermentation processes Trends Biotechnol. 20 2002 103 105
22. J.M. Brass, K. Krummen, and C. Moll-Kaufmann Quality assurance after process changes of the production of a therapeutic antibody Pharm. Acta Helv. 71 1996 395 403
23. D.A. Parkins, and U.T. Lashmar The formulation of biopharmaceutical products Pharm. Sci. Technol. Today 3 2000 129 136
24. D.J.A. Crommelin, G. Storm, R. Verrijk, L. de Leede, W. Jiskoot, and W.E. Hennink Shifting paradigms: biopharmaceuticals versus low molecular weight drugs Int. J. Pharm. 266 2003 3 16
25. Department of Health and Human Services, Guidance for Industry: Comparability Protocols - Chemistry, Manufacturing, and Controls Information Draft Guidance, September 2004, http://www.fda.gov/cder/guidance/protcmc.pdf
26. T.M. Leib, C.J. Pereira, and J. Villadsen Bioreactors: a chemical engineering perspective Chem. Eng. Sci. 56 2001 5485 5497
27. A. Durand Bioreactor designs for solid state fermentation Biochem. Eng. J. 13 2003 113 125
28. Y.-L. Hsu, and W.-T. Wu A novel approach for scaling-up a fermentation system Biochem. Eng. J. 11 2002 123 130
29. European Commission Directorate General III, The rules governing medicinal products in the European Union, Good Manufacturing Practices - Medicinal Products for Human and Veterinary Use, vol. 4, 1998 ed., http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm
30. M. Katz Planning ahead for manufacturing facility changes: a case study in outsourcing Pharm. Technol. 25 3 2001 160 164
31. R. Lias, and S. Fogerty The squeeze in contract biomanufacturing Pharm. Technol. Eur. 14 2002 31 34